INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...

Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial. Robert Stromberg, who has worked on blockbuster movies including “Avatar” and ...

After picking up the European rights to Eli Lilly’s Emgality and Rayvow late last year, women’s health outfit Organon is upping its migraine accord with the Big Pharma company. Organon has expanded ...

(RTTNews) - Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration has approved Emgality or galcanezumab-gnlm 120 mg injection for the preventive treatment of migraine in adults.

Emgality (fremanezumab) is a migraine medication prescribed to reduce the number and severity of migraine attacks in adults. Although no single migraine treatment works for everyone, some people have ...

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine. The Food and Drug ...